ArticleScientific reports2025
Determination of miRNA in tear extracellular vesicles significantly associated with treatment-requiring retinopathy of prematurity: a pilot study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Tiny messengers, big impact: unlocking the power of extracellular vesicles in neonatal health and disease. a systematic review.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Retinopathy of prematurity (ROP) develops in some premature infants and may be characterized by permanent severe retinal damage necessitating early detection and prompt treatment. The purpose of this study was to investigate whether specific miRNAs in tear extracellular vesicles (EVs) are associated with the development of ROP requiring treatment. Tear samples were collected from 47 infants, including 33 with ROP and 14 without ROP; of the ROP group, 18 infants required treatment. The miRNAs expressed in EVs were profiled by real-time PCR array. An exploratory analysis of differential miRNA expression using tear EV samples from 35 infants was performed. Network analysis conducted for the miRNAs for ROP requiring treatment revealed critical networks of miRNAs linked to IGF1R and VEGF. A machine learning study utilizing the random forest model identified 13 miRNAs with high importance score for the treatment-requiring ROP eyes. After adjustments for birth weight, miR-520a-5p was identified as a candidate marker. Network analysis confirmed a significant association of miR-520a-5p with the VEGF-centered network. When the Gradient boosting decision tree was applied, miR-520a-5p discriminated treatment-requiring ROP with accuracy of 77.8% and an area under the curve (AUC) of 0.889. For the validation phase, 12 unanalyzed infants were examined for the diagnostic accuracy of miR-520a-5p, and the findings confirmed a high diagnostic accuracy of 91.7% and AUC of 0.875 for treatment-required ROP eyes. Notably, miR-520a-5p expression was strongly influenced by infant immaturity, as reflected by gestational age. These findings provide new insights into ROP pathophysiology and suggest that tear-derived miRNAs, particularly those in EVs, may serve as potential biomarkers and inform future therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.